argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
argenx (ARGX) reported new VYVGART results in myasthenia gravis (MG) and CIDP alongside neuromuscular pipeline data.
Phase 3 ocular MG scores improved further after two additional treatment cycles in antibody-positive and triple-seronegative patients. In anti-AChR antibody-negative generalized MG, mean daily-activity score improvements of approximately 5 points were maintained through Week 52. A U.S. analysis of more than 1,100 patients associated earlier VYVGART treatment with greater improvement.
In CIDP, an interim analysis followed patients beyond five years. A Phase 4 study found 87% remained on VYVGART Hytrulo through 12 weeks after starting it one week after their last IVIg dose. Phase 2 empasiprubart data in multifocal motor neuropathy and Phase 1b adimanebart walking measures in congenital myasthenic syndrome also showed improvements.
argenx (ARGX) reports the results of its Extraordinary General Meeting of Shareholders and the appointment of Thomas M. Brakel and Khurem Farooq as non-executive directors to the Board.
Chairperson Tim Van Hauwermeiren said the new directors bring leadership and expertise that support argenx’s long-term “Vision 2030,” focused on scientific innovation, shareholder value and patient impact. Detailed voting results and related meeting documents are made available on the company’s investor website.
argenx (Euronext & Nasdaq: ARGX) announced that its management will participate in two investor events in September 2026: the Wells Fargo 21st Annual Healthcare Conference with a fireside chat on September 8 at 9:30 a.m. ET in Boston, and the Morgan Stanley 24th Annual Global Healthcare Conference with a fireside chat on September 14 at 9:15 a.m. ET in New York. Live webcasts and 30-day replays will be available via the argenx investor website.
argenx (Euronext & Nasdaq: ARGX) announced completion of its acquisition of Forte Biosciences (Nasdaq: FBRX), adding FB102, a first-in-class anti-CD122 antibody, to its immunology pipeline. FB102 has clinical proof-of-concept in vitiligo and celiac disease and is described as having potential across multiple autoimmune indications.
According to argenx, FB102 complements existing antibody programs such as efgartigimod, empasiprubart, adimanebart and ARGX-121 by targeting pathogenic T-cell and NK-cell activity. argenx completed a cash tender offer through a subsidiary at $77.00 per Forte share. As of expiration, 19,894,879 shares were validly tendered and not withdrawn, which, together with shares already owned by argenx and affiliates, represented approximately 87.13% of Forte’s outstanding common stock. These shares were accepted for payment.
Following the tender offer, argenx completed a merger of its wholly owned subsidiary into Forte. All remaining Forte shares were converted into the right to receive $77.00 in cash per share, subject to tax withholding. Forte became a wholly owned subsidiary of argenx, and Forte’s common stock will cease trading on the Nasdaq Capital Market.
argenx (NASDAQ: ARGX) and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) reported positive topline results from the global Phase 3 ALKIVIA trial of subcutaneous efgartigimod (VYVGART Hytrulo) in adults with autoimmune myositis. The study met its primary endpoint, showing a 15.4‑point greater mean Total Improvement Score (TIS) at Week 52 versus placebo in the combined IMNM and DM population (47.95 vs 32.56; p=0.0011).
Prespecified analyses showed a 14.8‑point TIS benefit in IMNM (45.05 vs 30.24; p=0.0048) and a similar 14.5‑point improvement in DM (51.51 vs 36.96; p=0.1093). Improvements emerged by Week 4, were sustained through one year with corticosteroid tapering, and all six TIS core measures favored efgartigimod. The safety profile was well‑tolerated and consistent with prior efgartigimod studies. argenx holds exclusive Greater China rights with Zai Lab, which recruited Chinese patients.
argenx (Euronext & Nasdaq: ARGX) reported positive topline results from the Phase 3 ALKIVIA trial of subcutaneous VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM).
The study met its primary endpoint: in the combined IMNM+DM population, efgartigimod achieved a 15.4‑point greater mean Total Improvement Score (TIS) at Week 52 versus placebo (47.95 vs 32.56; p=0.0011). Treatment benefits emerged by Week 4 and were sustained through one year despite protocol-mandated steroid tapering.
Prespecified analyses showed the Week 52 primary endpoint was also met in IMNM alone, with a 14.8‑point TIS advantage (45.05 vs 30.24; p=0.0048). In DM, a similar 14.5‑point improvement (51.51 vs 36.96; p=0.1093) was observed, though statistical significance was not reached in this smaller cohort. All six TIS core measures favored efgartigimod, and the safety profile was consistent with prior experience.
argenx (Euronext & Nasdaq: ARGX) has launched a cash tender offer, through its wholly owned subsidiary Avena Merger Sub, to acquire all outstanding shares of Forte Biosciences (Nasdaq: FBRX) at $77.00 per share, net to the seller in cash, without interest and subject to withholding taxes.
The offer is made under a July 26, 2026 Merger Agreement among argenx, the Purchaser and Forte. Following acceptance of shares and satisfaction or waiver of conditions, Purchaser will merge into Forte under DGCL Section 251(h), making Forte a wholly owned subsidiary of argenx, with remaining shares also converted into the right to receive $77.00 in cash per share.
The offer expires at one minute after 11:59 p.m. Eastern Time on August 26, 2026, unless extended or earlier terminated. Closing is subject to a Minimum Condition (more than 50% of outstanding shares, including those already owned by Purchaser and its affiliates, being validly tendered and not withdrawn) and expiration or termination of the Hart-Scott-Rodino antitrust waiting period, among other conditions. The offer is not subject to a financing condition. Forte’s Board has filed a Schedule 14D-9 with the SEC recommending that stockholders accept the offer and tender their shares. Offer materials and the Forte board’s recommendation are available via the SEC and company investor relations websites.
argenx (Euronext & Nasdaq: ARGX) will hold an Extraordinary General Meeting of Shareholders at 15:00 CEST on September 17, 2026 at Freshfields LLP, Strawinskylaan 10, Amsterdam. Shareholders may attend in person or by proxy, with e-voting and meeting documentation available via the argenx and ABN AMRO websites.
argenx (ARGX) entered a definitive agreement to acquire Forte Biosciences (FBRX) for $77 per share in cash, implying an equity value of approximately $2.2 billion. The price reflects an about 86% premium to Forte’s volume-weighted average price since its July 9, 2026 Phase 1b vitiligo data.
Through a wholly owned subsidiary, argenx will launch a cash tender offer for all outstanding Forte shares, followed by a back-end merger at the same price. The deal, funded entirely from cash on hand, is not subject to a financing condition and is expected to close in Q3 2026, subject to customary conditions including majority tender and Hart-Scott-Rodino clearance. The transaction adds Forte’s lead asset FB102, a first-in-class anti-CD122 antibody with Phase 1b data in vitiligo and celiac disease and potential additional autoimmune indications, to argenx’s immunology pipeline.
argenx (Euronext & Nasdaq: ARGX) reported strong half year 2026 results, driven by VYVGART growth. Second quarter 2026 product net sales reached $1.5 billion, up 60% year-over-year and 17% quarter-over-quarter, contributing to $2.8 billion product net sales for the first six months.
Total operating income was $1.5 billion for Q2 and $2.9 billion for H1 2026, with operating profit of $494 million in Q2 and $887 million in H1. Profit for the period rose to $472 million in Q2 and $838 million in H1, compared to $245 million and $415 million in 2025.
argenx expanded the U.S. label for VYVGART and VYVGART Hytrulo to cover all generalized myasthenia gravis serotypes and advanced multiple registrational studies across myositis, MMN, ITP, Sjogren’s disease and Graves’ disease. Cash, cash equivalents and current financial assets totaled $5.2 billion at June 30, 2026, supporting its Vision 2030 pipeline and commercial plans.